

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): ~~Use of rapamycin and its structural analogues for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia~~ A method of treating beta-thalassaemia comprising administering a medicament comprising a pharmaceutically effective amount of rapamycin or a structural analogue thereof to a patient in need of such treatment.

2. (currently amended): ~~Use~~ The method of treating beta-thalassaemia according to claim 1, wherein the structural analogue is selected from the group comprising 7- (N-hydroxy)- acyl analogues, carbamoyl analogues and ureide analogues of rapamycin.

3. (currently amended): ~~Use~~ The method of treating beta-thalassaemia according to claim 1, wherein the rapamycin or the structural analogue is in combination with at least one further modifier of the transcription process selected from the group consisting of cytosine arabinoside, retinoic acid, ~~retinoic acid~~, plicamycin, mithramycin, hydroxyurea, guanine, guanosine, triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).

Appln. No.: 10/519,990
Amendment

4. (currently amended): ~~Use~~ The method of treating beta-thalassaemia according to claim 2 , wherein the rapamycin or the structural analogue is in combination with at least one further modifier of the transcription process selected from the group consisting of cytosine arabinoside, ~~retinoic acid~~, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine, triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).